Premium
CHEMOTHERAPY OF ADVANCED GASTRIC CANCER
Author(s) -
Gill P. Grantley,
Jones Alan M.,
Abbott Richard
Publication year - 1983
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1983.tb02434.x
Subject(s) - medicine , chemotherapy , mitomycin c , gastric carcinoma , cancer , fluorouracil , oncology , disease , gastroenterology , combination chemotherapy , surgery
Twenty‐eight patients with inoperable or metastatic gastric cancer were treated with combination chemotherapy using 5‐fluorouracil, adriamycin and mitomycin‐C (FAM). Twenty‐one patients had measurable disease parameters and 57 per cent of these experienced a major regression of disease following chemotherapy. The median survival of the responding patients was 13.2 months compared with 6.8 months in the group who did not achieve a major response. These results demonstrate the sensitivity of gastric carcinoma to this drug combination.